|
gptkbp:instanceOf
|
gptkb:antipsychotic_medication
gptkb:thioxanthene_derivative
|
|
gptkbp:approvedBy
|
1978
|
|
gptkbp:ATCCode
|
N05AF05
|
|
gptkbp:brand
|
Acuphase
Clopixol
|
|
gptkbp:CASNumber
|
53772-83-1
|
|
gptkbp:chemicalFormula
|
C22H25ClN2OS
|
|
gptkbp:contraindication
|
gptkb:pheochromocytoma
coma
CNS depression
|
|
gptkbp:developedBy
|
gptkb:Lundbeck
|
|
gptkbp:drugClass
|
typical antipsychotic
|
|
gptkbp:eliminationHalfLife
|
19 days (depot)
20 hours (oral)
|
|
gptkbp:form
|
zuclopenthixol acetate
zuclopenthixol decanoate
zuclopenthixol dihydrochloride
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:alpha-1_adrenergic_receptor_antagonist
histamine H1 receptor antagonist
dopamine D1 and D2 receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
gptkb:C_(Australia)
|
|
gptkbp:proteinBinding
|
98%
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular injection
|
|
gptkbp:sideEffect
|
gptkb:orthostatic_hypotension
constipation
weight gain
sedation
dry mouth
extrapyramidal symptoms
|
|
gptkbp:synonym
|
cis(Z)-clopenthixol
|
|
gptkbp:usedFor
|
schizophrenia
psychosis
acute mania
|
|
gptkbp:bfsParent
|
gptkb:N05AH03
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
zuclopenthixol
|